FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance

Feng Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Meng Xu(First Affiliated Hospital of Jinan University)
Frontiers in Oncology
February 10, 2023
10.3389/fonc.2023.1088444
Cited by 4

Related Papers

Positive feedback regulation of type I interferon by the interferon‐stimulated gene STING
|EMBO Reports|2015|145
Retinoid X receptor α attenuates host antiviral response by suppressing type I interferon
|Nature Communications|2014|64
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer
|EMBO Molecular Medicine|2021|56
Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer
|Theranostics|2021|30
IFI16 Isoforms with Cytoplasmic and Nuclear Locations Play Differential Roles in Recognizing Invaded DNA Viruses
|The Journal of Immunology|2021|16